Skip to main navigation

Skip to Content

Overview
News & Events
- News Releases
- Events & Presentations
Governance
Stock Information
Financials
- SEC Filings
Resources

News Releases

Year

Sep 03, 2026

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 01, 2026

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Aug 11, 2026

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Aug 06, 2026

Tango Therapeutics Announces Executive Chair Transition

Jun 22, 2026

Tango Therapeutics Appoints Robert Azelby to Board of Directors

Jun 09, 2026

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

Jun 08, 2026

Tango Therapeutics Announces Proposed $500 Million Public Offering

Jun 08, 2026

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

Jun 05, 2026

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 13, 2026

Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 18

Print

RSS Feeds

Email Alerts

Contact IR

Tango Therapeutics, Inc
201 Brookline Avenue, Suite 901
Boston, Massachusetts 02215
Tel: +1-857-320-4900

contact | careers | Cookie Policy |